Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 14/20 | 1.00 |
| ▸ | CCR2 | P41597 | 7/20 | 1.00 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1716387 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2ARHGDIA | |
| Hydrochloric Acid SCHEMBL2457372 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2ARHGDIA | |
| Hydrochloric Acid SCHEMBL2457485 | 0.98 | ROCK2 (0.96) | ROCK2ROCK1CCR2ARHGDIA | |
| SCHEMBL658944 | 0.96 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL600089 | 0.93 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL5409256 | 0.91 | ROCK2 (0.83) | ROCK2ROCK1CCR2ARHGDIA | |
| SCHEMBL1717251 | 0.91 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL1716784 | 0.90 | ROCK2 (0.81) | ROCK2ROCK1CCR2 | |
| SCHEMBL1716838 | 0.90 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| Hydrochloric Acid SCHEMBL5409061 | 0.90 | ROCK2 (0.82) | ROCK2ROCK1CCR2ARHGDIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1256574-B1 | NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-01-18 | — | — | EP | claimed |
| EP-1616577-B1 | 2-chloro-6,7-dimethoxy-N-5 [5-(1)H- indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride for use in repairing corneal perception. | SENJU PHARMA CO (JP) | 2011-09-21 | — | — | EP | claimed |
| WO-2008022182-A1 | METHODS FOR PROMOTING COUPLING BETWEEN BONE FORMATION AND RESORPTION | THE UAB RESEARCH FOUNDATION (US) | 2008-02-21 | — | — | WO | claimed |
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2004-05-27 | — | — | US | claimed |
| EP-1256574-A1 | NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-13 | — | — | EP | claimed |
| EP-4338751-B1 | COMBINATION OF SEPETAPROST AND NETARSUDIL FOR USE IN THE PROPHYLAXIS OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | SANTEN PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-20250090544-A1 | ANTIPSYCHOTIC AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12201602-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240293411-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION | 2024-09-05 | — | — | US | disclosed |
| US-20240245668-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-07-25 | — | — | US | disclosed |
| US-11974994-B2 | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-4338751-A2 | MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND RHO-ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE INHIBITOR | Santen Pharmaceutical Co., Ltd. (JP) | 2024-03-20 | — | — | EP | disclosed |
| EP-1616577-A1 | AGENT FOR REPAIRING CORNEAL PERCEPTION | Senju Pharmaceutical Co., Ltd. (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-20050245509-A1 | Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins | SANTEN PHARMACECUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1568382-A1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND &bgr;-BLOCKER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1541151-A1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1256574-A1 | NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201602-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | CIT, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885CCR2 4031/4885 |
| US-11974994-B2 | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | PTGIS, PTGIR, PTGS1 | ROCK2 539/4885ROCK1 725/4885CCR2 4770/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885CCR2 2824/4885 |
| US-20240245668-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | ROCK2 539/4885ROCK1 725/4885CCR2 4770/4885 |
| US-20240293411-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | JAK1, ROCK1, JAK3 | ROCK2 4/4885ROCK1 2/4885CCR2 1137/4885 |
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | TNK2, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885CCR2 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.